GlassScriptPhysician profile
Chad A Perry
NPI 1508980947
$28,340.58
in general payments reported to CMS, 2019-2025
28 companies · $4,973 in 2025
The $4,973 reported for 2025 was more than what 98% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,455 · 2022: $3,771 · 2023: $4,272 · 2024: $11K · 2025: $4,973.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Consulting Fee: $4,625 · Travel and Lodging: $1,112 · Education: $303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,074.96 |
| Consulting Fee | $4,625.00 |
| Travel and Lodging | $1,111.54 |
| Education | $303.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $9,463.68 | 2021-2025 | Tremfya |
| Abbvie INC. | $5,066.33 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $3,405.94 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $2,435.09 | 2021-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $1,725.52 | 2021-2025 | |
| Dermavant Sciences, INC. | $1,079.06 | 2022-2024 | Vtama |
| Incyte Corporation | $1,055.78 | 2021-2025 | Opzelura |
| Leo Pharma INC. | $964.58 | 2022-2025 | Adbry |
| Ucb, INC. | $742.38 | 2021-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $568.01 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Amgen INC. | $468.98 | 2021-2025 | Otezla, Otezla |
| Pfizer INC. | $428.94 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $240.45 | 2021-2025 | Ilumya |
| Revance Therapeutics, INC. | $143.14 | 2025 | Daxxify |
| Galderma Laboratories, L.P. | $139.01 | 2024-2025 | Nemluvio, Aklief |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $125.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $85.10 | 2022 | |
| Organon LLC | $39.87 | 2025 | Vtama |
| Biofrontera INC. | $22.24 | 2021 | |
| Fresenius Kabi USA, LLC | $19.02 | 2023 | Idacio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $17.84 | 2021 | |
| Arcutis Biotherapeutics, INC. | $17.68 | 2025 | Zoryve |
| Botanix Sb INC | $17.28 | 2025 | Sofdra |
| Bayer Healthcare Pharmaceuticals INC. | $16.62 | 2021 | |
| Paratek Pharmaceuticals, INC. | $14.53 | 2025 | Nuzyra |
| Sanofi-Aventis U.S. LLC | $14.50 | 2021 | |
| Sandoz INC. | $12.74 | 2021 | |
| Genentech USA, INC. | $11.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Perry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.